New eye drug PRO-169 takes on lucentis in major trial
NCT ID NCT05217680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new eye medication called PRO-169 against a standard drug (ranibizumab) for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. About 509 adults with diabetes took part, receiving injections into the eye over one year. The goal was to see if PRO-169 works as well as the standard treatment at improving eyesight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SalaUno Salud, S.A.P.I. de C.V.
Mexico City, 06030, Mexico